1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Esclerosis Múltiple

Esclerosis Múltiple

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J.

    Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 90: 105787-105787.

    [doi:10.1016/j.msard.2024.105787]

  • Saposnik G, Monreal E, Medrano N, García-Domínguez JM, Querol L, Meca-Lallana JE, Landete L, Salas E, Meca-Lallana V, García-Arcelay E, Agüera-Morales E, Martínez-Yélamos S, Gómez-Ballesteros R, Maurino J, Villar LM, Caminero AB.

    Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 90: 105838-105838.

    [doi:10.1016/j.msard.2024.105838]

  • Domínguez-Mozo MI, Casanova I, Monreal E, Costa-Frossard L, Sainz-de-la-Maza S, Sainz-Amo R, Aladro-Benito Y, Lopez-Ruiz P, De-Torres L, Abellán S, Garcia-Martinez MA, De-la-Cuesta D, Lourido D, Torrado A, Gomez-Barbosa C, Linares-Villavicencio C, Villar LM, López-De-Silanes C, Arroyo R, Alvarez-Lafuente R.

    Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(18): .

    [doi:10.3390/ijms251810012]

  • Santas E, Villar S, Palau P, Llàcer P, de la Espriella R, Miñana G, Lorenzo M, Núñez-Marín G, Górriz JL, Carratalá A, Rodríguez E, Bayes-Genís A, Sanchis J, Núñez J.

    High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure.

    SCIENTIFIC REPORTS . 14(1): 21672-21672.

    [doi:10.1038/s41598-024-72137-0]

  • Navarrete-Pérez A, Gómez-Melero S, Escribano BM, Galvao-Carmona A, Conde-Gavilán C, Peña-Toledo MÁ, Villarrubia N, Villar LM, Túnez I, Agüera-Morales E, Caballero-Villarraso J.

    MIND Diet Impact on Multiple Sclerosis Patients: Biochemical Changes after Nutritional Intervention.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(18): .

    [doi:10.3390/ijms251810009]

  • Tortosa-Carreres J, Cubas-Núñez L, Piqueras M, Castillo-Villalba J, Quintanilla-Bordàs C, Quiroga-Varela A, Villarrubia N, Monreal E, Álvarez G, Gasque-Rubio R, Forés-Toribio L, Carratalà-Boscà S, Lucas C, Sanz MT, Ramió-Torrentà L, Villar LM, Casanova B, Laiz B, Pérez-Miralles FC.

    Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

    JOURNAL OF NEUROIMMUNOLOGY . 394: 578428-578428.

    [doi:10.1016/j.jneuroim.2024.578428]

  • Chico-Garcia, Juan Luis, Amo, Raquel Sainz, Monreal, Enric, de la Maza, Susana Sainz, Jorge, Fernando Rodriguez, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa Maria.

    Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study

    MULTIPLE SCLEROSIS JOURNAL . 30(10): 1239-1349.

    [doi:10.1177/13524585241272960]

  • Sainz de la Maza S, Rodero-Romero A, Monreal E, Chico-García JL, Villarrubia N, Rodríguez-Jorge F, Fernández-Velasco JI, Sainz-Amo R, Costa-Frossard L, Masjuan J, Villar LM.

    COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.

    Frontiers in immunology . 15: 1439393-1439393.

    [doi:10.3389/fimmu.2024.1439393]

  • Sainz-Amo R, Rodero Romero A, Monreal E, Chico García JL, Fernández Velasco JI, Villarrubia N, Veiga González JL, Sainz de la Maza S, Rodríguez Jorge F, Masjuan J, Costa-Frossard L, Villar LM.

    Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.

    Frontiers in immunology . 15: 1454474-1454474.

    [doi:10.3389/fimmu.2024.1454474]

  • Rodero-Romero A, Monreal E, Sainz-Amo R, García Domínguez JM, Villarrubia N, Veiga-González JL, Fernández-Velasco JI, Goicochea-Briceño H, Rodríguez-Jorge F, Sainz de la Maza S, Chico-García JL, Muriel A, Masjuan J, Costa-Frossard L, Villar LM.

    Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(14): .

    [doi:10.3390/ijms25147808]

  • Lunemann JD, Hegen H, Villar LM, Rejdak K, Sao-Aviles A, Carbonell-Mirabent P, Sastre-Garriga J, Mongay-Ochoa N, Berek K, Martínez-Yélamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke JN, Rosenstein I, Alvarez-Lafuente R, Castillo-Trivino T, Otaegui D, Llufriu S, Blanco Y, Sánchez López AJ, Garcia Merino JA, Fissolo N, Gutierrez L, Villacieros-Álvarez J, Monreal E, Valls-Carbó A, Wiendl H, Montalban X, Comabella M.

    Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

    Neurology(R) neuroimmunology & neuroinflammation . 11(4): .

    [doi:10.1212/NXI.0000000000200270]

  • Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.

    XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I).

    REVISTA DE NEUROLOGIA . 79(1): 21-29.

    [doi:10.33588/rn.7901.2024170]

  • Calabrese M, Preziosa P, Scalfari A, Colato E, Marastoni D, Absinta M, Battaglini M, De Stefano N, Di Filippo M, Hametner S, Howell OW, Inglese M, Lassmann H, Martin R, Nicholas R, Reynolds R, Rocca MA, Tamanti A, Vercellino M, Villar LM, Filippi M, Magliozzi R.

    Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.

    ANNALS OF NEUROLOGY . 96(1): 1-20. Nº de citas: 3

    [doi:10.1002/ana.26913]

  • Dominguez-Mozo MI, Galán V, Ramió-Torrentà L, Quiroga A, Quintana E, Villar LM, Costa-Frossard L, Fernández-Velasco JI, Villarrubia N, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R.

    A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.

    Frontiers in immunology . 15: 1384411-1384411.

    [doi:10.3389/fimmu.2024.1384411]

  • Chico-Garcia JL, Sainz-Amo R, Monreal E, Rodriguez-Jorge F, Sainz de la Maza S, Masjuan J, Villar LM, Costa-Frossard França L.

    Passive assessment of tapping speed through smartphone is useful for monitoring multiple sclerosis.

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 86: 105595-105595. Nº de citas: 1

    [doi:10.1016/j.msard.2024.105595]

  • Núñez-Torrón Stock C, Jiménez Chillón C, Martín Moro F, Marquet Palomanes J, Piris Villaespesa M, Roldán Santiago E, Rodríguez Martín E, Chinea Rodríguez A, García Gutiérrez V, Moreno Jiménez G, López Jiménez J, Herrera Puente P.

    Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia.

    Frontiers in Oncology . 14: 1394648-1394648.

    [doi:10.3389/fonc.2024.1394648]

  • Pérez-Torre P, López-Sendón JL, Mañanes Barral V, Parees I, Fanjul-Arbós S, Monreal E, Alonso-Canovas A, Martínez Castrillo JC.

    Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice.

    Neurologia . 39(4): 340-344.

    [doi:10.1016/j.nrleng.2021.08.005]

  • Pérez-Torre P, López-Sendón JL, Mañanes Barral V, Parees I, Fanjul-Arbós S, Monreal E, Alonso-Canovas A, Martínez Castrillo JC.

    Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice.

    NEUROLOGIA . 39(4): 340-344. Nº de citas: 4

    [doi:10.1016/j.nrl.2021.08.004]